Ana Kiess is an Oncology physician affiliated with Johns Hopkins University. OpenAlex indexes 185 publications with 4,655 citations (h-index 32); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
401 S Broadway
Suite 1440
Baltimore, MD 212312431
Telephone
443-287-7528Registry record last updated 18 Dec 2014.
Clinical trials
- PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20251 payment
- VOXIMETRY, INC.Program year20231 payment
- Novartis Pharmaceuticals CorporationProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
48%Opioid Agonist24%Oxycodone Hcl100%Part D<11 patientsSNRI24%Venlafaxine Hcl Er100%Part D<11 patientsCancer & immunology
30%Gonadotropin Releasing Hormone Receptor Antagonist30%Orgovyx100%Part D<11 patientsGenitourinary & hormones
22%alpha-Adrenergic Blocker22%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2025 per NIH RePORTER. The latest:
- Imaging, Dosimetry and Radiobiology for α-particle Emitter Radiopharmaceutical Therapy
Johns Hopkins University
FY2025$2,569,180P01CA272222
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
The Lancet Oncology
2024 - Guiding principles on the education and practice of theranostics
European Journal of Nuclear Medicine and Molecular Imaging
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”